NervGen Pharma Corp. (NGEN) has announced the pricing of a public offering consisting of 24 million shares and warrants at $2.50 per unit, aiming to raise approximately $60 million. The proceeds will primarily fund clinical studies for its lead candidate, NVG-291, a neuroreparative peptide targeting spinal cord injuries, which has received Fast Track and Orphan Drug designations from regulatory bodies. The offering is expected to close on May 26, 2026, pending customary conditions.
This capital raise comes at a challenging time for NGEN, which has seen its stock fluctuate between $1.50 and $6.30 over the past year. Following the announcement, shares dropped 20.38% in after-hours trading to $2.93, reflecting investor concerns about dilution and the company’s ability to execute its clinical strategy.
For market professionals, the immediate takeaway is the potential volatility in NGEN’s stock as the market digests the implications of this offering and its impact on the company’s funding and operational trajectory.
Source: nasdaq.com